Revised Prices of Anti-Cancer Medicines to Come into Effect from 9th November;
PIB National (English) · Published 7 November 2026 · Last updated
The NPPA capped trade margins at 30% for 137 anti-cancer medicines, enforcing price cuts of up to 96.45% across 1,031 formulations from 9 November 2026.
Key points
- The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, capped trade margins on the Maximum Retail Price (MRP) of 137 anti-cancer drugs.
- The price rationalisation was executed under notification SO 5690 (E) dated 17 October 2026, following recommendations of an Expert Committee constituted by the Directorate General of Health Services (DGHS) under the Ministry of Health and Family Welfare.
- The revised MRPs across all covered oncology formulations take statutory effect nationwide from 9 November 2026.
- A total of 76 pharmaceutical companies submitted revised price filings covering 1,225 formulations across 121 drugs, resulting in price cuts for 1,031 formulations.
- Over 600 oncology drug brands registered price reductions exceeding 50%, with the maximum observed price drop reaching 96.45%.
- The price revision is estimated to deliver direct annual out-of-pocket savings of ₹3,502.31 crore to cancer patients and households.
- Between 10 and 15 drugs out of the 137 identified formulations are not yet launched in India, but will automatically attract the capped trade margins upon commercial entry.
- Manufacturers are permitted an annual price revision under Paragraph 20(1) of the Drugs (Prices Control) Order, 2013 (DPCO 2013), provided overall trade margins remain capped at the 30% ceiling.
- The regulatory regime mandates State Drug Controllers to oversee compliance across manufacturing facilities, distributors, retail chemists, and private and public hospitals.
- All retailers, dealers, hospitals, and medical institutions are legally bound to prominently display the revised MRP schedule both within their physical premises and on their web portals.
Background
- High out-of-pocket expenditure on oncology drugs has historically driven catastrophic health spending in India due to unrestrained supply-chain markups on non-scheduled formulations.
- Under the Drugs (Prices Control) Order, 2013, scheduled formulations receive ceiling prices, whereas non-scheduled formulations were traditionally monitored only for annual retail price increases not exceeding 10%.
- To curb exorbitant intermediary profits without crushing domestic manufacturing incentives, the Trade Margin Rationalization (TMR) approach was devised to cap margins at the point of sale to retailers.
- The Directorate General of Health Services (DGHS) under the Ministry of Health & Family Welfare set up an Expert Committee to audit cancer treatment costs and identify high-cost antineoplastic molecules.
- On 17 October 2026, the NPPA issued gazette notification SO 5690 (E) invoking emergency public-interest price-fixing powers to operationalise DGHS recommendations on 137 cancer therapies.
UPSC relevance, Prelims facts and Mains angle for this issue are in the full SWAदेSH note.
Original report: PIB National (English)